Concern about the lack of access to affordable, well-characterized and analytically validated renewable affinity reagents and supporting resources has been discussed among representatives of the cancer scientific community. In order to drive the development of a central community core that would help accelerate biomarker discovery and validation, cancer diagnostics development, and therapeutics monitoring, the National Cancer Institute (NCI) launched the Antibody Characterization Program. This program within the Clinical Proteomic Technologies for Cancer initiative (CPTC), provides reagents and other critical resources to support protein/peptide measurement and analysis efforts. For More information on this program and reagents currently available go to http://proteomics.cancer.gov. The CPTC Reagents Data Portal provides information and access for a large number of reagents in the CPTC initiative. Currently, monoclonal antibodies are being generated and characterized to proteins associated with human cancer. For each protein target, three monoclonal antibodies are generated and characterized using standardized assays that include (non inclusive list): isotype, SDS-PAGE, Western Blot, ELISA, Immunohistochemistry, Immuno Mass Spectroscopy and Surface Plasmon Resonance. Monoclonal antibodies and hybridoma cells are made available to the research community through the Developmental Studies Hybridoma Bank (DSHB) at the University of Iowa or other third-party vendors. All antibodies are expressed, purified, produced and characterized using standard operating procedures (SOPs) that are freely accessible to the public. Since not all antibodies selected will be applicable to specific utilities, reasonable efforts are made to select antibodies with as broad utility as possible.
Because this is a highly sought after resource, the NCI may not be able to satisfy all requests for antibody generation. Concomitantly, there are no guarantees that if the NCI attempts to make antibodies to the target protein request, that the antibodies will be successfully generated and/or useful in the application desired. The NCI reserves the right to deny requests that are deemed incompatible with the mission and goals of the NCI.
Submission Period: April 8, 2013 - July 12, 2013. Target selection notification will be on or before August 30, 2013. Please note that all materials (i.e. proteins/peptides) to be used must be ready and available at time of submission.
Requests will be reviewed and considered for merit based on their justification and contribution to existing NCI-funded projects. Priority will be given to projects applying the antibodies to proteomic research. Requests should be submitted electronically by completing the accompanying form.For questions, please contact Dr. Tara Hiltke of the NCI: